BRPI0716455A8 - desenvolvimento de componentes de vacina do vírus da dengue - Google Patents

desenvolvimento de componentes de vacina do vírus da dengue

Info

Publication number
BRPI0716455A8
BRPI0716455A8 BRPI0716455A BRPI0716455A BRPI0716455A8 BR PI0716455 A8 BRPI0716455 A8 BR PI0716455A8 BR PI0716455 A BRPI0716455 A BR PI0716455A BR PI0716455 A BRPI0716455 A BR PI0716455A BR PI0716455 A8 BRPI0716455 A8 BR PI0716455A8
Authority
BR
Brazil
Prior art keywords
dengue virus
utr
mutation
development
vaccine components
Prior art date
Application number
BRPI0716455A
Other languages
English (en)
Portuguese (pt)
Inventor
R Murphy Brian
e blaney Joseph
S Whitehead Stephen
Original Assignee
Government Of The Us Secretary Of The Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The Us Secretary Of The Department Of Health And Human Services filed Critical Government Of The Us Secretary Of The Department Of Health And Human Services
Priority to BR122020023372-9A priority Critical patent/BR122020023372B1/pt
Publication of BRPI0716455A2 publication Critical patent/BRPI0716455A2/pt
Publication of BRPI0716455A8 publication Critical patent/BRPI0716455A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0716455A 2006-08-15 2007-08-15 desenvolvimento de componentes de vacina do vírus da dengue BRPI0716455A8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020023372-9A BR122020023372B1 (pt) 2006-08-15 2007-08-15 Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83772306P 2006-08-15 2006-08-15
PCT/US2007/076004 WO2008022196A2 (en) 2006-08-15 2007-08-15 Development of dengue virus vaccine components

Publications (2)

Publication Number Publication Date
BRPI0716455A2 BRPI0716455A2 (pt) 2014-03-04
BRPI0716455A8 true BRPI0716455A8 (pt) 2019-01-15

Family

ID=39083099

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0716455A BRPI0716455A8 (pt) 2006-08-15 2007-08-15 desenvolvimento de componentes de vacina do vírus da dengue
BR122020023372-9A BR122020023372B1 (pt) 2006-08-15 2007-08-15 Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020023372-9A BR122020023372B1 (pt) 2006-08-15 2007-08-15 Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica

Country Status (15)

Country Link
US (9) US8337860B2 (pl)
EP (2) EP2589602B1 (pl)
CN (2) CN103602689B (pl)
AU (1) AU2007285929B2 (pl)
BR (2) BRPI0716455A8 (pl)
CA (2) CA3004991C (pl)
CY (1) CY1118003T1 (pl)
DK (2) DK2589602T3 (pl)
ES (1) ES2585553T3 (pl)
HU (1) HUE029333T2 (pl)
LT (1) LT2589602T (pl)
PL (1) PL2589602T3 (pl)
PT (1) PT2589602T (pl)
SI (1) SI2589602T1 (pl)
WO (1) WO2008022196A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903126C (en) * 2002-01-10 2020-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
ATE481982T1 (de) * 2002-05-03 2010-10-15 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
PL2589602T3 (pl) 2006-08-15 2016-11-30 Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi
AU2010256845B2 (en) * 2009-06-01 2016-09-22 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
US9878031B2 (en) 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
EP2968516B1 (en) * 2013-03-15 2022-01-12 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
JP2016523251A (ja) 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
JP6671364B2 (ja) * 2014-11-02 2020-03-25 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル ワクチンおよび診断開発のための組換えデングウイルスについての方法および組成物
ES2981476T3 (es) * 2014-12-22 2024-10-09 Merck Sharp & Dohme Llc Composiciones de vacunas contra el virus del dengue y métodos de uso de las mismas
US9730989B2 (en) 2015-07-02 2017-08-15 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
CA2999881A1 (en) 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
WO2017056101A1 (en) 2015-09-30 2017-04-06 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
CA3016697A1 (en) 2016-03-11 2017-09-14 The Johns Hopkins University Live attenuated zika virus vaccine
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
BR112019016309A2 (pt) * 2017-02-14 2020-03-31 The Board Of Regents Of The University Of Texas System Vírus da zika atenuado vivo com deleção 3'utr, vacina contendo o mesmo e uso da mesma
US10240130B2 (en) 2017-02-15 2019-03-26 The Board Of Regents Of The University Of Texas System CDNA clone-launched platform for high-yield production of inactivated zika virus
WO2019112921A1 (en) 2017-12-07 2019-06-13 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
BR112022001476A2 (pt) 2019-08-16 2023-10-03 Takeda Vaccines Inc Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit
US20240226338A9 (en) * 2021-02-26 2024-07-11 Duke University Compositions For and Methods of Improving Gene Therapy
US20240150729A1 (en) * 2021-03-19 2024-05-09 Merck Sharp & Dohme Llc A closed-system upstream manufacturing process for dengue virus production
JP2025508605A (ja) * 2022-02-22 2025-03-26 フートル バイオ エルティーディーエー． 次世代ｍＲＮＡワクチン
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
ATE481982T1 (de) * 2002-05-03 2010-10-15 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
WO2006036233A1 (en) * 2004-06-14 2006-04-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services West nile viruses with mutations in the 3’ terminal stem and loop secondary structure for use as live virus vaccines
PL2589602T3 (pl) * 2006-08-15 2016-11-30 Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi

Also Published As

Publication number Publication date
EP2589602A2 (en) 2013-05-08
USRE46042E1 (en) 2016-06-28
US10724007B2 (en) 2020-07-28
US20220251521A1 (en) 2022-08-11
LT2589602T (lt) 2016-10-10
US10160957B2 (en) 2018-12-25
EP2054428A2 (en) 2009-05-06
US12203100B2 (en) 2025-01-21
US8337860B2 (en) 2012-12-25
US20190119654A1 (en) 2019-04-25
US20100104598A1 (en) 2010-04-29
DK2054428T3 (da) 2013-08-26
ES2585553T3 (es) 2016-10-06
EP2589602A3 (en) 2013-10-09
PL2589602T3 (pl) 2016-11-30
WO2008022196A3 (en) 2009-03-12
CN103602689B (zh) 2016-08-24
CN103602689A (zh) 2014-02-26
WO2008022196A2 (en) 2008-02-21
CN101657463B (zh) 2013-09-18
AU2007285929B2 (en) 2013-09-05
EP2589602B1 (en) 2016-04-06
CA2661296A1 (en) 2008-02-21
CA3004991A1 (en) 2008-02-21
CN101657463A (zh) 2010-02-24
US20130089567A1 (en) 2013-04-11
EP2054428B1 (en) 2013-06-05
US20240084269A1 (en) 2024-03-14
US9090873B2 (en) 2015-07-28
HUE029333T2 (en) 2017-03-28
US11746335B2 (en) 2023-09-05
CY1118003T1 (el) 2017-05-17
SI2589602T1 (sl) 2016-08-31
BRPI0716455A2 (pt) 2014-03-04
PT2589602T (pt) 2016-07-13
CA2661296C (en) 2018-06-26
DK2589602T3 (en) 2016-07-25
US11332722B2 (en) 2022-05-17
US20180171308A1 (en) 2018-06-21
AU2007285929A1 (en) 2008-02-21
CA3004991C (en) 2022-08-30
BR122020023372B1 (pt) 2021-11-30
AU2007285929A2 (en) 2009-04-23
US20250236848A1 (en) 2025-07-24
EP2054428B9 (en) 2013-11-13
US20200318083A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
BRPI0716455A8 (pt) desenvolvimento de componentes de vacina do vírus da dengue
AR069882A1 (es) Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e
AR063606A1 (es) Estabilizacion de vacunas mediante liofilizacion
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
MX360728B (es) Metodos y composiciones para virus vivos atenuados.
BRPI0520330A2 (pt) adjuvante a base de ácido polinosìnico-policitidìlico
BR0111830A (pt) Método de produção de partìculas semelhantes ao vìrus da influenza (vlps), vlps da influenza, vlps quiméricas, proteìnas da influenza, composições imunogênica e farmacêutica, métodos de imunizar contra a infecção causada pelo vìrus da influenza ou por um microorganismo patogênico outro que não o vìrus da influenza, método de tratamento, e, célula hospedeira transfectada, infectada ou transformada com uma molécula de dna recombinante
JP2010511022A5 (pl)
CO2021001926A2 (es) Composiciones de escherichia coli y métodos de estas
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
MX2009004223A (es) Protocolo de inmunizacion contra los 4 serotipos del dengue.
MX347210B (es) Vacunas combinadas para prevención de infecciones por virus porcino.
BRPI0814899A2 (pt) Composição, vacina, metodo para amenizar um ou mais sintomas associados à infecção com o virus da influenza em um individuo e método para reduzir a probabilidade de infecção com o virus da influeza em um individuo"
AR072302A1 (es) Pestivirus atenuados. composicion inmunogenica. metodo.
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
CO6290700A2 (es) Una vacuna que comprende una emulsion y una bacterina tratada con calor que comprende una suspension de la bacteria muerta
PH12016500761A1 (en) Infant formulas containing a 2-fucosylated oligosaccharide for treatment or prevention of influenza infection
BR112015012968A2 (pt) composições e métodos de uso
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
BRPI0904020B8 (pt) composição vacinal contra o vírus da dengue, e, kit
AR059005A1 (es) Virus quimericos del dengue
ATE479440T1 (de) Virusstämme und zusammensetzungen des prrs- syndroms (porcine reproductive und respiratory syndrome) von schweinen
BRPI0616224B8 (pt) composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]